| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 07/11/2023 |
3. Issuer Name and Ticker or Trading Symbol
60 DEGREES PHARMACEUTICALS, INC. [ SXTP ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock, $0.0001 par value per share ("Common Shares") | 1,108,337 | I(1)(2)(3) | By Knight Therapeutics International SA |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
| Explanation of Responses: |
| 1. In addition to Knight Therapeutics Inc., a Canadian corporation ("Knight Parent"), this Form 3 is being jointly filed by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary" and collectively with Knight Parent, the "Reporting Persons"). |
| 2. Knight Subsidiary directly beneficially owns 1,108,337 Common Shares. |
| 3. Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of 60 Degrees Pharmaceuticals, Inc. (the "Issuer") beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 3 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose. |
| Remarks: |
| Exhibit 99.1 (Joint Filer Information) incorporated herein by reference. |
| KNIGHT THERAPEUTICS INTERNATIONAL S.A. By: /s/ Arvind Utchanah Name: Arvind Utchanah Title: President of the Board of Directors | 12/14/2023 | |
| KNIGHT THERAPEUTICS INC. By: /s/ Samira Sakhia Name: Samira Sakhia Title: President and Chief Executive Officer | 12/14/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
Exhibit 99.1
Joint Filer Information
|
Name of Joint Filer:
|
Knight Therapeutics Inc.
|
|
Address of Joint Filer:
|
3400 de Maisonneuve W. Suite 1055, Montréal, Quebec H3Z 3B8
|
|
Relationship of Joint Filer to Issuer:
|
10% Beneficial Owner
|
|
Issuer Name and Ticker or Trading Symbol:
|
60 DEGREES PHARMACEUTICAL, INC. [SXTP]
|
|
Date of Event Requiring Statement:
|
July 11, 2023
|
|
Designated Filer:
|
Knight Therapeutics Inc.
|
|
Signature:
|
KNIGHT THERAPEUTICS INC.
|
By:
|
/s/ Samira Sakhia | ||
|
Name: Samira Sakhia
|
|||
|
Title: President and Chief Executive Officer
|
|||
|
Date: December____, 2023
|
|||
|
Name of Joint Filer:
|
Knight Therapeutics International S.A.
|
|
Address of Joint Filer:
|
Dr. Luis Bonavita 1294, of. 2004, Montevideo, Uruguay
|
|
Relationship of Joint Filer to Issuer:
|
10% Beneficial Owner
|
|
Issuer Name and Ticker or Trading Symbol:
|
60 DEGREES PHARMACEUTICAL, INC. [SXTP]
|
|
Date of Event Requiring Statement:
|
July 11, 2023
|
|
Designated Filer:
|
Knight Therapeutics Inc.
|
|
Signature:
|
KNIGHT THERAPEUTICS INTERNATIONAL S.A.
|
By:
|
/s/ Arvind Utchanah |
|
|
|
Name: Arvind Utchanah
|
|
||
|
Title: President of the Board of Directors
|
|
||
|
Date: December____, 2023
|
|
||
2